SCHEMBL932166

SCHEMBL932166

O=C(CBr)c1ccc(O)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.48
ALDH1A1 P00352 3/20 0.45
MAPK1 P28482 1/20 0.45
CHRNA7 P36544 1/20 0.45
LMNA P02545 3/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HSP90AB1 P08238 1/20 0.43
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
CES2 O00748 2/20 0.41
ESR1 P03372 1/20 0.41
SHBG P04278 1/20 0.41
ESR2 Q92731 1/20 0.41
ESRRG P62508 1/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
ALOX12 P18054 1/20 0.40
RAB9A P51151 1/20 0.40
MIF P14174 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL962932 0.82 CES2 (0.61) PTPN1CES2RAB9ACES1
SCHEMBL29669985 0.82 CES2 (0.61) PTPN1CES2RAB9ACES1
SCHEMBL177181 0.81 HSP90AB1 (0.67) ALDH1A1MAPK1CHRNA7LMNAHTT
SCHEMBL691531 0.81 DGAT1 (0.61) PTPN1ALDH1A1LMNASMN1; SMN2CES2
SCHEMBL29993519 0.81 DGAT1 (0.61) PTPN1ALDH1A1LMNASMN1; SMN2CES2
SCHEMBL3844607 0.80 HSP90AB1 (0.66) PTPN1ALDH1A1MAPK1LMNAHTT
SCHEMBL31105825 0.80 HSP90AB1 (0.66) PTPN1ALDH1A1MAPK1LMNAHTT
SCHEMBL1352151 0.79 PTPN1 (0.41) PTPN1CES2CES1DGAT1
SCHEMBL3918063 0.79 GSK3B (0.50) PTPN1ALDH1A1MAPK1LMNASMN1; SMN2
SCHEMBL30217466 0.79 GSK3B (0.50) PTPN1ALDH1A1MAPK1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488519-B1 PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT PF MEDICAMENT (FR) 2015-06-10 EP disclosed
US-8889711-B2 Pyrazolopyridine derivatives as anticancer agent PIERRE FABRE MEDICAMENT (FR) 2014-11-18 US disclosed
US-8889711-B2 Pyrazolopyridine derivatives as anticancer agent PIERRE FABRE MEDICAMENT (FR) 2014-11-18 US disclosed
US-8889711-B2 Pyrazolopyridine derivatives as anticancer agent PIERRE FABRE MEDICAMENT (FR) 2014-11-18 US disclosed
US-20140296212-A1 SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2014-10-02 US disclosed
US-20140296212-A1 SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2014-10-02 US disclosed
US-8648067-B2 Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands CEPHALON, INC. (US) 2014-02-11 US disclosed
US-8648067-B2 Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands CEPHALON, INC. (US) 2014-02-11 US disclosed
US-20120245170-A1 PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT PIERRE FABRE MEDICAMENT (FR) 2012-09-27 US disclosed
US-20120245170-A1 PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT PIERRE FABRE MEDICAMENT (FR) 2012-09-27 US disclosed
US-6603008-B1 Inhibit the biosynthesis of prostaglandins by intervention of the action of the enzyme cyclooxygenase on arachidonic acid PFIZER INC. 2003-08-05 US disclosed
US-20030144280-A1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents PFIZER INC. (US) 2003-07-31 US disclosed
EP-1104760-B1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents PFIZER PROD INC (US) 2003-03-12 EP disclosed
US-6399660-B1 AMINOETHYLPHENOXYACETIC ACID COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (JP) 2002-06-04 US disclosed
US-20020045654-A1 Sulfonylbenzene compounds as anti-inflammatory/analgesic agents ANDO KAZUO (JP) 2002-04-18 US disclosed
US-6294558-B1 ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS PFIZER INC. 2001-09-25 US disclosed
EP-1104760-A1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents Pfizer Products Inc. (US) 2001-06-06 EP disclosed
EP-1086097-A1 SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS PFIZER INC. (US) 2001-03-28 EP disclosed
EP-1002791-A1 AMINOETHYLPHENOXYACETIC ACID DERIVATIVES AND DRUGS FOR PAIN REMISSION AND CALCULI REMOVAL PROMOTION IN URINARY LITHIASIS Kissei Pharmaceutical Co., Ltd. (JP) 2000-05-24 EP disclosed
WO-1999064415-A1 SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245170-A1 PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT DPYD, TYMP, ABCB1 PTPN1 2206/4885ALDH1A1 170/4885MAPK1 665/4885
US-20140296212-A1 SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS HRH3, HRH4, HRH2 PTPN1 2317/4885ALDH1A1 2032/4885MAPK1 1855/4885
US-20020045654-A1 Sulfonylbenzene compounds as anti-inflammatory/analgesic agents CNR1, PTGER1, PTGS1 PTPN1 2032/4885ALDH1A1 599/4885MAPK1 561/4885
US-20030144280-A1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents PTGS1, PTGS2, SULT2A1 PTPN1 1956/4885ALDH1A1 421/4885MAPK1 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.